Department of Surgery, Kochi Medical School, Kochi, Japan;
Department of Surgery, Kochi Medical School, Kochi, Japan.
Anticancer Res. 2023 Aug;43(8):3701-3707. doi: 10.21873/anticanres.16553.
BACKGROUND/AIM: We report the case of a patient with gastric and bone metastases arising from an invasive lobular carcinoma of the breast coexisting with ductal carcinoma at the same time.
A 68-year-old woman with gastric and right costal tumors was referred to our hospital. Esophagogastroduodenoscopy (EGD) revealed irregular, slightly elevated lesions extending from the gastric body to the antrum, and biopsy specimens revealed a poorly differentiated adenocarcinoma. Furthermore, abdominal contrast-enhanced computed tomography (CT) revealed extensive wall thickening with homogeneous enhancement in the stomach. 18F-2-deoxy-2-fluoro-glucose positron emission tomography (FDG-PET) showed intense FDG uptake in the right mammary gland and right third rib. Moreover, fine-needle aspiration of the third right rib lump and the right breast mass lesion was performed, and subsequent pathological investigations revealed metastatic adenocarcinoma and invasive ductal carcinoma, respectively. Immunohistochemical examination revealed that estrogen receptor was strongly positive (>95%) in breast cancer and focally positive (<5%) in gastric cancer with bone metastasis. In addition, another right breast tumor was detected by breast magnetic resonance imaging (MRI), and biopsy revealed invasive lobular carcinoma that matched the histological findings of bone and gastric lesions, including immunohistochemical examination. The patient was treated with an aromatase inhibitor, a CDK4/6 inhibitor, and a receptor activator of nuclear factor-kappa B ligand (RANKL) monoclonal antibody. She showed no symptoms or disease progression at 9-month follow-up after the initiation of systemic drug treatment.
Invasive lobular carcinoma can metastasize to the gastrointestinal tract, and new treatment developments are expected as more cases will accumulate in the future.
背景/目的:我们报告了一例同时患有乳腺浸润性小叶癌和导管癌的胃和骨转移患者。
一名 68 岁女性因胃和右肋部肿瘤就诊于我院。食管胃十二指肠镜(EGD)显示从胃体延伸至胃窦的不规则、轻度隆起性病变,活检标本显示为低分化腺癌。此外,腹部增强 CT 显示胃广泛壁增厚且均匀强化。18F-2-脱氧-2-氟葡萄糖正电子发射断层扫描(FDG-PET)显示右乳腺和右第三肋骨摄取大量 FDG。此外,对第三右肋骨肿块和右乳腺肿块进行了细针抽吸,随后的病理检查显示转移性腺癌和浸润性导管癌。免疫组化检查显示乳腺癌中雌激素受体强阳性(>95%),胃伴骨转移癌中弱阳性(<5%)。此外,还通过乳腺磁共振成像(MRI)检测到另一个右乳腺肿瘤,活检显示浸润性小叶癌,与骨和胃病变的组织学发现一致,包括免疫组化检查。患者接受了芳香酶抑制剂、CDK4/6 抑制剂和核因子-κB 配体(RANKL)单克隆抗体治疗。在开始全身药物治疗后 9 个月的随访中,她没有出现症状或疾病进展。
浸润性小叶癌可转移至胃肠道,随着未来更多病例的积累,预计会有新的治疗方法发展。